Bilthoven Biologicals
Budget
€200 — €0
EP Access
0
accredited persons
Staff
7
2.2 FTE
EU Grants
€26,500,000
Mission & Goals
BBio is a Netherlands-based end-to-end vaccine manufacturer of viral and bacterial vaccines, with its facilities in Bilthoven - Utrecht Science Park Bilthoven. A carve-out of the former Netherlands Vaccine Institute, it was acquired by Serum Institute of India in 2012 and today employs a little under 500 people. The company has a long-standing track record in supplying vaccines to European markets and works with global health partners such as UNICEF, PAHO, and WHO & /GAVI. With the manufacturing of polio vaccines, BBio is key contributor to the worldwide program for polio eradication. BBio is part of the EU funded pandemic preparedness program, having ever-warm vaccine manufacturing facilities. Furthermore, BBio offers its end-to-end manufacturing and market access capabilities, to collaborators and innovators of biologicals, thereby increasing equitable access to medical interventions in Europe.
EU Legislative Interests
Policies, Consultations and Legislations that cater to the Healthcare sector; especially in preventative health (vaccines and biologics)
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Holland Bio Vaccines Europe
Additional Information
The amounts mentioned above (Section 14) are rounded & part of the Pandemic Preparedness funding received from EU Institutions (HERA/EUFab).These are reservation fees for keeping our pandemic preparedness facilities "ever warm".
Commissioner Meetings
No recorded meetings with EU commissioners.